Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)

Overview

This 39-week, active controlled, study is designed to assess long-term efficacy, safety and tolerability of lumiracoxib 100mg od in patients with osteoarthritis (OA) of the knee who participated in the 13-week core CCOX189A2361 study.

Full Title of Study: “A 39-week, Double-blind, Active-controlled Extension to CCOX189A2361, a 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Trial of 2 Different Dose Regimens of Lumiracoxib (100 mg od and 200 mg od Initial Dose for Two Weeks Followed by 100 mg od) in Patients With Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double
  • Study Primary Completion Date: November 2004

Interventions

  • Drug: lumiracoxib

Clinical Trial Outcome Measures

Primary Measures

  • To compare lumiracoxib 100mg od to celecoxib 200mg od in treating osteoarthritis (OS) of the target knee with respect to:
  • Overall OA pain intensity in the target knee on a 0-100 mm Visual Analog Scale (VAS) at 26 weeks.
  • Patient’s global assessment of disease activity on a 0-100mm VAS at 26 weeks.
  • Patient’s functional status using the WOMAC total score at 26 weeks

Secondary Measures

  • To assess the safety and tolerability profile of lumiracoxib as compared to celecoxib
  • To assess the efficacy of lumiracoxib as compared to celecoxib with respect to:
  • Overall OA pain intensity on a 0-100 mm VAS by visit
  • Patient’s global assessment of disease activity by visit
  • Physician’s global assessment of disease activity by visit
  • Patient’s functional status using the WOMAC 3.1 LK sub-scale scores and total score by visit
  • Usage of rescue medication
  • Response to treatment according to OARSI criteria by visit

Participating in This Clinical Trial

Inclusion Criteria

  • Any patient who completed the core study 2361 may enter the extension trial upon signing informed consent. A patient is defined as completing if he/she completed the core study 2361 up to and including Visit 6 (week 13) without a major protocol violation. Exclusion Criteria:

  • Those patients for whom continued treatment in the extension study is not considered appropriate by the treating physician – Those patients who were non-compliant or who demonstrated a major protocol violation in the core study. Other protocol-defined inclusion/exclusion criteria may apply

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Novartis
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.